Work

2743TiP First-in-human (FIH) phase I/II study of ADCE-D01, a urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload, in patients with metastatic and/or unresectable soft tissue sarcoma (STS)

Year: 2025

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.3353

Authors: P. Schoeffski, S. Bauer, J-Y. Blay, R.G. Maki, S. Patel, J.C. Trent, B. Wilky, M.A. Wibroe, L.H. Ottesen

Institutions: KU Leuven, Centre Léon Bérard, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center, University of Colorado Health, University of Colorado Cancer Center, University of Colorado Anschutz, Adcendo ApS (Denmark)

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415940039

FWCI:

Cites:

Cited by:

Related to: 10